Gigacloud Technology Inc vs Johnson & Johnson — how do they compare? Gigacloud Technology Inc trades at $38 (market cap $1.40B), while Johnson & Johnson trades at $249.75 (market cap $594.63B). The key difference: Johnson & Johnson is far larger — about 424.7× Gigacloud Technology Inc's market cap, and Johnson & Johnson pays a 2.17% dividend while Gigacloud Technology Inc pays none. Which is the better fit depends on your goals.
| GCT | JNJ | |
|---|---|---|
Market Cap | $1.40B | $594.63B |
Sector | Technology | Health |
52-Week High | $51.80 | $267.24 |
52-Week Low | $20.97 | $162.98 |
Enterprise Value | $1.51B | $627.57B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.17% |
Signals from Pluang's Aura AI — not financial advice
GigaCloud Technology (GCT) trades at $38.01, up 7.37% on the day, showing strong momentum. The stock demonstrates robust fundamentals with a P/E of 9.5, net income margin of 10.8%, and consistent earnings beats in recent quarters. Technical indicators show a bullish overall signal despite mixed moving averages and oscillators. Recent news highlights the company's inclusion in TIME's 'World's Growth Leaders 2026' list and strong Q1 2026 results with 32% YoY revenue growth.
The outlook appears positive with analyst consensus at 'Buy' (67% buy rating), strong profitability metrics (ROE 32.1%), and expanding international presence. Key risks include potential market volatility, competitive pressures in B2B logistics, and execution risks in new market expansion. The stock presents an opportunity given its valuation multiples below growth rates and consistent operational execution.
Johnson & Johnson (JNJ) trades at $249.42, down 1.75% over 24 hours, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q2 2026 EPS of $2.90, beating estimates, and raised full-year guidance. Revenue grew 6.6% annually, supported by strong pharmaceutical sales. Analyst consensus is bullish with a $281 price target, and the stock offers a stable dividend with recent payouts of $1.34 per share.
Outlook remains positive due to robust fundamentals, innovation in medtech and pharmaceuticals, and dividend king status. Risks include patent expirations, regulatory pressures, and macroeconomic volatility. The current valuation at P/E 28.66 may limit near-term upside, but long-term growth prospects appear solid.
Trailing returns across standard periods
Latest headlines on both assets
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →